{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-089164","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2024-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.080403+00:00","generated_at":"2026-06-04T01:27:08.590524+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TScan Therapeutics appoints Chrystal U. Louis as CMO; Dr. Debora Barton departs","bullets":["Chrystal U. Louis, M.D., M.P.H., named Chief Medical Officer effective April 8, 2024.","Dr. Louis brings 20+ years of hematology/oncology drug development and cell therapy experience.","Outgoing CMO Dr. Debora Barton departing for personal reasons; will continue as consultant.","Dr. Barton joined TScan in July 2022; contributed to heme program and solid tumor initiation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-089164","json":"https://secwatch.observer/filing/0001193125-24-089164.json","markdown":"https://secwatch.observer/filing/0001193125-24-089164.md","text":"https://secwatch.observer/filing/0001193125-24-089164.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312524089164/0001193125-24-089164-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312524089164/d810490d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:27:08.590524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}